VEIP

Drug Overview:

VEIP is a highly intensive combination chemotherapy regimen used primarily as salvage therapy. It combines three cytotoxic agents, Etoposide, Ifosfamide, and Cisplatin, with the uroprotectant Mesna.

• Generic Name: Etoposide (VP-16) + Ifosfamide + Cisplatin + Mesna
• US Brand Names: Etopophos®, Toposar® (Etoposide); Ifex® (Ifosfamide); Platinol® (Cisplatin); Mesnex® (Mesna)
• Drug Class: Combination Chemotherapy Regimen (Topoisomerase II Inhibitor, Alkylating Agent, Platinum Agent, Uroprotectant)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: The component drugs are individually FDA-approved. The VEIP regimen is a standard, evidence-based combination protocol used in complex oncology management.

What Is It and How Does It Work? (Mechanism of Action):

The VEIP regimen is a multi-modal cytotoxic protocol designed for deep tumor cell eradication by attacking cancer cell DNA at various stages of the cell cycle.

• Etoposide (VP-16): Topoisomerase II Inhibition, It inhibits the Topoisomerase II enzyme, stabilizing DNA-enzyme complexes and preventing the repair of double-strand breaks. This causes lethal DNA damage, primarily in late S- and G₂-phase cells, forcing apoptosis (programmed cell death).
• Ifosfamide: DNA Alkylation, This prodrug is activated by liver enzymes into isophosphoramide mustard, a potent alkylating agent. It forms covalent bonds with DNA bases, creating cross-links that block DNA replication and transcription, leading to cell cycle arrest and death.
• Cisplatin: Platinum Coordination Complex, Inside the cell, cisplatin forms reactive platinum complexes that bind to purine bases, creating intra-strand and inter-strand DNA cross-links. The resulting structural damage triggers irreversible DNA repair failure and apoptosis.
• Mesna: Uroprotection, This protective agent concentrates in the urinary system, where it binds to and detoxifies acrolein, the urotoxic metabolite of ifosfamide, thereby preventing hemorrhagic cystitis (severe bladder damage).

What Is It and How Does It Work? (Mechanism of Action):

The VEIP regimen is a multi-modal cytotoxic protocol designed for profound tumor cell eradication by attacking cancer cell DNA at multiple points in the cell cycle.

• Molecular Target: Each agent targets a different component of DNA integrity and replication: Etoposide inhibits Topoisomerase II; Ifosfamide (as its active metabolite) acts as a DNA alkylating agent; Cisplatin forms platinum-DNA cross-links.
• Cellular Impact: Etoposide stabilizes the DNA-Topoisomerase II complex, preventing repair of double-strand breaks. Ifosfamide metabolites create covalent DNA cross-links, physically blocking replication. Cisplatin adducts cause severe DNA helix distortion. Mesna, a uroprotectant, detoxifies a harmful ifosfamide metabolite in the bladder.
• Result: The synergistic action creates cumulative, irreparable DNA damage. This triggers catastrophic failure of DNA repair mechanisms, leading to cell cycle arrest and the initiation of apoptosis (programmed cell death) across a broad population of rapidly dividing cancer cells.
• Chemotherapy Regimen: VEIP is a combination chemotherapy regimen, leveraging the non-overlapping mechanisms and toxicities of multiple cytotoxic drugs to maximize tumor cell kill and overcome potential resistance.

FDA Approved Clinical Indications:

VEIP is a cornerstone regimen in the salvage setting following the failure of initial platinum-based treatment.

Oncological Uses

1. Germ Cell Tumors (GCTs): Second-line or salvage therapy for refractory or recurrent metastatic testicular cancer (both seminoma and non-seminoma) and for ovarian or extragonadal GCTs after first-line platinum-based chemotherapy (e.g., BEP) fails. Patient selection is guided by prognostic factors at relapse, including prior treatment response and disease burden.

Non-Oncological Uses

1. The VEIP regimen has no approved non-oncological indications.

Dosage and Administration Protocols:

VEIP is a complex, high-intensity regimen typically administered in cycles lasting 21 days. The standard protocol below refers to a common five-day administration schedule, which mandates rigorous supportive care and inpatient monitoring.

Renal and Hepatic Dose Adjustments

• Renal Insufficiency: Cisplatin and Ifosfamide are nephrotoxic. Patients with severe renal impairment (Creatinine Clearance less than 30 mL/min) generally require significant dose reduction or substitution due to the high risk of acute renal failure.
• Hepatic Insufficiency: Dose reduction may be necessary for Etoposide and Ifosfamide, as they are metabolized by the liver, to mitigate potential toxicity.
• Hematologic Toxicity: Subsequent cycles are usually held or doses reduced if nadir blood counts have not recovered adequately by the scheduled start date.

Clinical Efficacy and Research Results:

For platinum-sensitive recurrent Germ Cell Tumors (GCTs), VEIP achieves high objective response rates, establishing it as a critical salvage option. Historical studies report complete response (CR) rates exceeding 50%, translating to durable long-term cure rates of 25-40% in the second-line setting.

• Contemporary Role and Evidence (2020-2025 Context): Recent trials, including the pivotal TIGER study, have compared conventional salvage chemotherapy (like VIP) to sequential high-dose chemotherapy (HDCT) with autologous stem cell transplant (ASCT). Current evidence indicates that for patients with an intermediate- or poor-prognosis profile at first relapse, two cycles of HDCT may offer a survival advantage. Therefore, VEIP is now often utilized as effective induction therapy to reduce tumor burden prior to proceeding with HDCT/ASCT, a strategy that optimizes outcomes.
• Prognostic Factors: Efficacy strongly correlates with the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic classification at relapse. Key factors include remission duration after first-line therapy (<2 years is unfavorable), the presence of non-pulmonary visceral metastases (e.g., liver, bone), and serum tumor marker levels (AFP, hCG).

Safety Profile and Side Effects:

The VEIP regimen carries significant, multi-organ toxicity risks requiring proactive management in an inpatient setting.

Black Box Warnings (for Component Drugs)

• Severe Myelosuppression: Universal, profound bone marrow suppression from all three agents, leading to high risk of febrile neutropenia and hemorrhage.
• Nephrotoxicity: Cisplatin causes cumulative, potentially irreversible kidney damage.
• Hemorrhagic Cystitis and Neurotoxicity: Ifosfamide risks severe bladder bleeding and dose-related encephalopathy.

Common Side Effects (>10%)

• Hematologic: Severe neutropenia (nadir day 10-14), anemia, thrombocytopenia.
• Gastrointestinal: Profound nausea/vomiting (highly emetogenic), diarrhea, mucositis.
• Constitutional: Severe fatigue, universal alopecia.
• Metabolic/Renal: Hypomagnesemia, hypocalcemia, elevated liver enzymes.

Serious Adverse Events

• Acute Renal Failure: High risk with inadequate hydration.
• Ifosfamide Encephalopathy: A neurotoxic syndrome managed with drug cessation and Methylene Blue.
• Cisplatin-Induced Ototoxicity: Permanent, high-frequency hearing loss; requires baseline audiogram.
• Secondary Malignancy: Long-term risk of treatment-related AML (t-AML), associated with etoposide.

Connection to Stem Cell and Regenerative Medicine (If Applicable):

VEIP is integrally connected to stem cell transplantation, forming a key component of modern curative-intent strategies.

Autologous Stem Cell Transplantation (ASCT): In current practice, VEIP serves dual roles: 1) As a mobilization regimen to stimulate release and collection of peripheral blood stem cells (PBSCs), and 2) As a cytoreductive “bridge” therapy to achieve maximal disease control prior to myeloablative high-dose chemotherapy (HDCT). The collected autologous stem cells are later reinfused to rescue the bone marrow, enabling the delivery of otherwise lethal chemotherapy doses.

Patient Management and Practical Recommendations:

Prior to Treatment (Pre-Testing & Planning)

• Laboratory Screening: Baseline CBC with differential, CMP (including calculated CrCl), and serum electrolytes (Mg, Ca, Phos).
• Baseline Assessments: Formal audiogram and neurologic assessment.
• Dental Evaluation: Comprehensive dental exam to address potential sources of infection before neutropenia.

Precautions and Monitoring During Treatment

• Aggressive Hydration: Mandatory IV hydration with normal saline before, during, and after cisplatin to ensure renal protection and adequate urine output.
• Anti-Emetic Prophylaxis: A multi-agent regimen (NK-1 antagonist, 5-HT3 antagonist, dexamethasone) is standard.
• Vigilant Monitoring: Daily assessment of renal function, fluid balance, and mental status for early signs of encephalopathy.

Do’s and Don’ts

• DO maintain rigorous oral/IV hydration as directed.
• DO report fever (≥100.4°F), hearing changes, numbness, or confusion immediately.
• DO adhere strictly to the scheduled supportive medications.
• DON’T ignore fever/chills—it is a febrile neutropenia emergency.
• DON’T take any new medications, supplements, or NSAIDs without oncology approval.
• DON’T engage in high-risk activities during the myelosuppressive nadir (days 7-14).

Legal Disclaimer:

This guide is for informational purposes only for international patients and healthcare professionals. It summarizes the standard clinical use and risks of the VEIP regimen based on current evidence. This is not medical advice. Dosing and protocols are highly individualized. Always consult your healthcare provider for questions about your specific condition or treatment.